A randomized, placebo-controlled, double-blinded, crossover trial of pioglitazone for severe asthma.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 28625806.
- Also identified by DOI 10.1016/j.jaci.2017.05.033 and PMC identifier 5723231.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe asthma.
Medical subject headings
- Asthma
- Hypoglycemic Agents
- Pioglitazone